Sironax
- Biotech or pharma, therapeutic R&D
Sironax focuses on aging, degeneration, rare diseases, and supportive care for cancer. Leading assets include an allosteric, brain-penetrant SARM1 inhibitor (Ph1 completed), a brain-penetrant RIPK1 inhibitor (Ph1 completed), a NAMPT activator (Ph1 ongoing), and a differentiated brain delivery platform for multiple modalities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}